Health TrialsbyHealthPanel

Angiogenic Biomarkers in Juvenile Idiopathic Arthritis

ConditionJuvenile Idiopathic Arthritis (JIA)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Greater than or equal to 16 years-old

Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital

No-opposition to the research

Patient with health insurance

Disqualifiers

Patient under curatorship or guardianship

Patient receiving french state medical aid

Trial population

Patients over (or egal) 16 years old with diagnosis of Juvenile Idiopathic Arthritis starting their follow up in adult rheumatology ward in Cochin hospital

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Blood sample

    Biological/Vaccine

    Addtional tube of blood needed for follow up of patients

  • Joint puncture

    Biological/Vaccine

    Joint puncture if needed according to routine care of the patients

Treatment groups

300 Participants
are divided into 1 treatment group
Group A: Juvenile Idiopathic Arthritis2 interventions

Trial outcomes

Primary outcomes

1

Dosage of angiogenic markers

Dosage of angiogenic markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

Time frame
5 years
2

Dosage of angiogenic markers

Dosage of angiogenic markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

Time frame
5 years
3

Dosage of inflammatory markers by ELISA method

Dosage of inflammatory markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

Time frame
5 years
4

Dosage of inflammatory markers by ELISA method

Dosage of inflammatory markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

Time frame
5 years

Secondary outcomes

1

Questionnaires

Severity of JIA

Time frame
5 years
2

Collection of treatments received

Severity of JIA

Time frame
5 years
3

Structural damage determined by x-rays

Structural damage determined by x-rays during follow up.

Time frame
5 years
4

Angiogenic biomarkers

Determine if sera angiogenic biomarkers are associated with clinical subtypes of JIA.

Time frame
At inclusion

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assistance Publique - Hôpitaux de Paris

Lead sponsor

URC-CIC Paris Descartes Necker Cochin

Collaborator

Source ClinicalTrials.gov
Apply now